1. Resolvin D1 reduces the immunoinflammatory response of the rat eye following uveitis.
- Author
-
Settimio R, Clara DF, Franca F, Francesca S, and Michele D
- Subjects
- Animals, Chemokines analysis, Cytokines analysis, Male, Rats, Rats, Sprague-Dawley, T-Lymphocytes immunology, Uveitis immunology, Docosahexaenoic Acids therapeutic use, Uveitis drug therapy
- Abstract
This study investigated whether the administration of resolvin D1 to rats with endotoxininduced uveitis (EIU) ameliorates the immuno-inflammatory profile of the eye. 24 h after the administration of 200 μg LPS into the footpad of Sprague-Dawley rats, severe changes of the structure of the eye occurred concomitantly with a severe inflammatory and immune response. These latter included strong infiltration of PMN leukocytes CD11b(+) T-lymphocytes CD4(+) and CD8(+) within the eye and a significant release of the cytokines/chemokines TNF-alpha, CXCL8, and RANTES too. Bolus of resolvin D1 (RvD1; 10-100-1000 ng/kg in 200 μL of sterile saline via the tail vein) significantly and dose-dependently (i) reduced the development of the ocular derangement caused by LPS; (ii) reduced the clinical score attributed to EIU; (iii) reduced the protein concentration and myeloperoxidase activity (MPO) in aqueous humor (AqH); and (iv) reduced neutrophils, T-lymphocytes, and cytokines within the eye.
- Published
- 2012
- Full Text
- View/download PDF